LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Nektar Therapeutics

Chiusa

72.86 -1.02

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

71.18

Massimo

74.55

Metriche Chiave

By Trading Economics

Entrata

6.1M

-36M

Vendite

615K

12M

EPS

-1.87

Margine di Profitto

-301.289

Dipendenti

61

EBITDA

6.9M

-29M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+73.04% upside

Dividendi

By Dow Jones

Utili prossimi

11 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

856M

2B

Apertura precedente

73.88

Chiusura precedente

72.86

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Nektar Therapeutics Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 feb 2026, 22:31 UTC

Utili

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb 2026, 22:18 UTC

Utili

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb 2026, 22:11 UTC

Utili

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb 2026, 21:52 UTC

Utili

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb 2026, 23:56 UTC

Discorsi di Mercato

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb 2026, 23:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

18 feb 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb 2026, 23:34 UTC

Discorsi di Mercato
Utili

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb 2026, 23:33 UTC

Discorsi di Mercato

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb 2026, 23:32 UTC

Discorsi di Mercato

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb 2026, 22:45 UTC

Utili

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb 2026, 22:44 UTC

Discorsi di Mercato

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb 2026, 22:37 UTC

Utili

Nutrien 4Q EPS $1.18 >NTR.T

18 feb 2026, 22:37 UTC

Utili

Nutrien 4Q Sales $5.34B >NTR.T

18 feb 2026, 22:35 UTC

Utili

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb 2026, 22:35 UTC

Utili

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb 2026, 22:30 UTC

Utili

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb 2026, 22:29 UTC

Utili

Kinross Gold 4Q EPS 75c >K.T

18 feb 2026, 22:22 UTC

Utili

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb 2026, 22:22 UTC

Discorsi di Mercato

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb 2026, 22:16 UTC

Utili

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb 2026, 22:05 UTC

Utili

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb 2026, 22:03 UTC

Utili

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb 2026, 22:02 UTC

Utili

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb 2026, 22:02 UTC

Utili

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb 2026, 22:02 UTC

Utili

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb 2026, 22:00 UTC

Utili

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb 2026, 22:00 UTC

Utili

Kinross Gold 4Q Sales $2.02B >KGC

18 feb 2026, 21:56 UTC

Utili

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb 2026, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Nektar Therapeutics Previsione

Obiettivo di Prezzo

By TipRanks

73.04% in crescita

Previsioni per 12 mesi

Media 123.43 USD  73.04%

Alto 165 USD

Basso 102 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Nektar Therapeutics - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

8

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.5949 / 0.7406Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

help-icon Live chat